Internal Reference Number: FOI_8341
Date Request Received: 12/12/2024 00:00:00
Date Request Replied To: 19/12/2024 00:00:00
This response was sent via: By Email
Request Summary: Request on Asthma
Request Category: Researcher
Question Number 1: How many patients have been treated (for any condition) in the last 4 months with: • Benralizumab • Dupilumab • Omalizumab • Reslizumab • Mepolizumab • Tezepelumab | |
Answer To Question 1: Please see our response to all questions of this FOI in the Excel spreadsheet attached. To accompany this answer to question 1 please also see the documents listed below: ![]() | |
Question Number 2: Of the patients treated in the last 4 months with any of the above products, please provide the number of patients by the following age-groups: • Age 6-11 • Age 12-17 • Age 18 and above | |
Answer To Question 2: Please see responses in excel spreadsheet. | |
Question Number 3: How many patients have been treated in the last 4 months by the Respiratory Medicine department ONLY with: • Dupilumab • Omalizumab | |
Answer To Question 3: Please see responses in excel spreadsheet. | |
Question Number 4: How many patients have been diagnosed with BOTH chronic sinusitis (ICD-10 code J32) AND nasal polyps (ICD-10 code J33) in the past year? Of these patients, how many have been treated in the last 4 months with: • Benralizumab • Dupilumab • Omalizumab • Reslizumab • Mepolizumab • Tezepelumab | |
Answer To Question 4: Please see responses in excel spreadsheet. | |
Please see Attachments: | |
To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.